AVX420

AVX420 is a small molecule drug candidate that acts as an inhibitor of cytosolic phospholipase A2 alpha (cPLA2α), an enzyme implicated in the development of cancer and inflammation. Developed by Coegin Pharma, with contributions from academic partners such as the Norwegian University of Science & Technology (NTNU), University of Athens, and UC San Diego, AVX420 has demonstrated promising preclinical activity in models of leukemia. The drug induces selective programmed cell death in blood cancer cells at low concentrations without affecting healthy T-cells, suggesting a favorable safety profile compared to conventional chemotherapies. In animal models of acute lymphoblastic leukemia (ALL), intravenous administration resulted in significant dose-dependent anti-leukemic effects with reduced risk for side effects typically associated with necrosis-inducing therapies. There are also indications that AVX420 may have potential applications beyond oncology due to its anti-inflammatory mechanism[1][2][3][4][7].

Other names

FOL026/AVX-420